Piper Sandler analyst Adam Maeder raised the firm’s price target on ResMed (RMD) to $260 from $252 and keeps a Neutral rating on the shares. The firm notes ResMed reported Q2 results that topped consensus estimates on the top and bottom-line. Piper acknowledges this was a solid quarter turned in by ResMed, but says it continues to take a wait-and-see approach at these valuation levels.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.